Edition:
United States

Immune Pharmaceuticals Inc (IMNP.PH)

IMNP.PH on Philadelphia Stock Exchange

3.00USD
28 Apr 2017
Change (% chg)

$-0.05 (-1.64%)
Prev Close
$3.05
Open
$3.00
Day's High
$3.00
Day's Low
$3.00
Volume
337
Avg. Vol
1,509
52-wk High
$12.39
52-wk Low
$2.21

IMNP.PH

Chart for IMNP.PH

About

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its... (more)
No analyst recommendations are available for IMNP.PH.

Overall

Beta: 1.87
Market Cap(Mil.): $26.11
Shares Outstanding(Mil.): 8.67
Dividend: --
Yield (%): --

Financials

  IMNP.PH Industry Sector
P/E (TTM): -- 29.08 30.08
EPS (TTM): -14.56 -- --
ROI: -89.95 13.73 13.25
ROE: -305.82 14.68 14.41

BRIEF-Immune Pharmaceuticals says board to pursue possible spin-off of Cytovia into separate, stand-alone company independent from Immune

* Board to pursue a possible spin-off of Cytovia into a separate, stand-alone company independent from immune

Apr 24 2017

BRIEF-Immune receives nasdaq letter

* Got notice from listing qualifications department of Nasdaq notifying that Co does not comply with Nasdaq's filing requirements Source text for Eikon: Further company coverage:

Apr 24 2017

BRIEF-Immune Pharma signs LOI with Pint Pharma

* Immune pharmaceuticals signs letter of intent with pint pharma regarding license and commercializion of ceplene® in latin america

Apr 20 2017

BRIEF-Immune Pharmaceuticals announces 1-for-20 reverse stock split

* Immune Pharmaceuticals announces 1-for-20 reverse stock split

Apr 12 2017

BRIEF-Immune Pharmaceuticals files for non-timely 10-K - SEC filing

* Files for non-timely 10-K - SEC filing Source text: (http://bit.ly/2no13te) Further company coverage:

Mar 31 2017

BRIEF-Immune Pharmaceuticals enters into a common stock purchase agreement with HLHW IV LLC

* On March 22 co entered into a common stock purchase agreement with HLHW IV LLC

Mar 23 2017

BRIEF-Immune Pharmaceuticals says granted additional time to comply with NASDAQ listing requirement

* Immune Pharmaceuticals granted additional time to comply with NASDAQ listing requirement Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-Immune Pharmaceuticals to announce launch of Remain

* Immune Pharmaceuticals announces the launch of Remain ™ , an international overall survival study with Ceplene® and low dose proleukin® in remission maintenance in acute myeloid leukemia

Feb 17 2017

BRIEF-Immune Pharmaceuticals enters into common stock purchase agreement with HLHW IV LLC

* Entered into a common stock purchase agreement with HLHW IV LLC- SEC filing

Feb 03 2017

BRIEF-Immune Pharmaceuticals appoints new chairman of board

* Immune pharmaceuticals appoints new chairman of the board of directors

Jan 27 2017

More From Around the Web

Competitors

Earnings vs. Estimates